logo

Japan Diabetes Drugs Market Size (2024 - 2029)

The Japan Diabetes Drugs Market is projected to experience growth over the forecast period, driven by an increasing prevalence of diabetes, particularly among the aging population. Factors such as sedentary lifestyles, unhealthy diets, and obesity contribute to the rising incidence of type 2 diabetes, which in turn influences the market size. The demand for diabetes management solutions, including oral antidiabetic drugs, is expected to rise as the population seeks to mitigate health risks associated with diabetes, such as cardiovascular and kidney disorders.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research Diabetes Drugs Market in Japan Market Size

Market Size of Japan Diabetes Drugs Industry

Japan Diabetes Drugs Market Summary
Study Period 2018 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 3.15 Billion
Market Size (2029) USD 4.03 Billion
CAGR (2024 - 2029) 4.98 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Japan Diabetes Drugs Market Analysis

The Japan Diabetes Drugs Market size is estimated at USD 3.15 billion in 2024, and is expected to reach USD 4.03 billion by 2029, growing at a CAGR of 4.98% during the forecast period (2024-2029).

While Type 1 diabetes is caused by an immune system malfunction, Type 2 diabetes is linked to leading a sedentary lifestyle, which results in the development of inherent resistance to insulin. Hence, Type 1 diabetes can be characterized as insulin-requiring, while Type 2 diabetes can be characterized as insulin-dependent diabetes. 

Japan has one of the largest elderly populations in the world which is more susceptible to the onset of type 2 diabetes. As Japan's population continues to age, the prevalence of diabetes increases as well. The monitoring and management of blood glucose levels are on the rise, to avoid negative consequences, such as cardiovascular diseases, kidney disorders, and many other conditions.

The prevalence of diabetes is increasing among the population, especially the elderly population, owing to unhealthy diets, obese population, and sedentary lifestyles. Various studies were conducted to assess the prescription patterns of oral antidiabetic drugs in Japanese patients with type 2 diabetes.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Japan Diabetes Drugs Industry Segmentation

Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Japan Diabetes Drugs Market is segmented into insulin drugs, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs. The report offers the value (in USD) and volume (in units) for the above segments.

Insulins
Basal or Long Acting Insulins
Bolus or Fast Acting Insulins
Traditional Human Insulins
Biosimilar Insulins
Oral Anti-diabetic drugs
Biguanides
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
SGLT-2 inhibitors
DPP-4 inhibitors
Sulfonylureas
Meglitinides
Non-Insulin Injectable drugs
GLP-1 receptor agonists
Amylin Analogue
Combination drugs
Insulin combinations
Oral Combinations
Need A Different Region Or Segment?
Customize Now

Japan Diabetes Drugs Market Size Summary

The Japan Diabetes Drugs Market is poised for significant growth, driven by the increasing prevalence of diabetes, particularly type 2, among the aging population. This rise is attributed to factors such as unhealthy diets, obesity, and sedentary lifestyles, which are prevalent in Japan. The market is characterized by a strong focus on oral anti-diabetic drugs, which are preferred due to their efficacy, safety, and cost-effectiveness. These drugs play a crucial role in managing blood glucose levels and reducing the risk of complications associated with diabetes, such as cardiovascular diseases and kidney disorders. The Japanese healthcare system supports this market growth through disease management programs and public health policies aimed at promoting lifestyle and dietary changes to prevent adult-onset diabetes.

The market landscape is consolidated, with major pharmaceutical companies like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca leading the charge. These companies are actively engaged in strategy-based mergers and acquisitions to expand their market presence and enhance revenue streams. The introduction of innovative products, such as SGLT-2 inhibitors, has further bolstered the market, offering effective management of blood glucose levels and cardiovascular risk factors. The economic burden of diabetes, exacerbated by co-morbidities, underscores the importance of well-organized medical insurance systems in Japan, which cover all medical fees and facilitate easy access to healthcare services. This supportive environment, coupled with ongoing advancements in diabetes management technologies, is expected to sustain the market's growth trajectory in the coming years.

Explore More

Japan Diabetes Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Insulins

      1. 2.1.1 Basal or Long Acting Insulins

      2. 2.1.2 Bolus or Fast Acting Insulins

      3. 2.1.3 Traditional Human Insulins

      4. 2.1.4 Biosimilar Insulins

    2. 2.2 Oral Anti-diabetic drugs

      1. 2.2.1 Biguanides

      2. 2.2.2 Alpha-Glucosidase Inhibitors

      3. 2.2.3 Dopamine D2 receptor agonist

      4. 2.2.4 SGLT-2 inhibitors

      5. 2.2.5 DPP-4 inhibitors

      6. 2.2.6 Sulfonylureas

      7. 2.2.7 Meglitinides

    3. 2.3 Non-Insulin Injectable drugs

      1. 2.3.1 GLP-1 receptor agonists

      2. 2.3.2 Amylin Analogue

    4. 2.4 Combination drugs

      1. 2.4.1 Insulin combinations

      2. 2.4.2 Oral Combinations

Japan Diabetes Drugs Market Size FAQs

The Japan Diabetes Drugs Market size is expected to reach USD 3.15 billion in 2024 and grow at a CAGR of 4.98% to reach USD 4.03 billion by 2029.

In 2024, the Japan Diabetes Drugs Market size is expected to reach USD 3.15 billion.

Japan Diabetes Drugs Market Report Snapshots

Japan Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)